Latest Headlines

  1. Audentes Therapeutics Announces Dosing Of First Patient In ASPIRO, A Phase 1/2 Clinical Trial Of AT132 For The Treatment Of X-Linked Myotubular Myopathy
    9/21/2017

    Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM)

  2. Eight More Agencies, Including ATF, Will Use STRmix™
    9/21/2017

    The federal Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has joined seven state and local agencies as the latest forensic labs in the U.S. to use STRmix,™ a sophisticated forensic software used by trained, experienced DNA experts to resolve mixed DNA profiles previously thought to be too complex to interpret

  3. Recapping Large Format Sample Storage Tubes Effectively
    9/21/2017

    Micronic, innovator in sample storage solutions, adds two new Screw Cap Recappers to its sample handling equipment line: the Univo Screw Cap Recapper SR006 and SR004

  4. GSK, AstraZeneca And Labcyte Form Alliance To Develop Acoustic Mass Spectrometry - A Novel Sample Handling Technology For MS-Based Drug Discovery
    9/20/2017

    Labcyte Inc. recently announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications.

  5. Sun Pharma Odomzo (Sonidegib) New Label Approval Shows Sustained Duration Of Response Of 26 Months In Treatment Of Locally Advanced Basal Cell Carcinoma
    9/20/2017

    Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries or associate companies) recently announced that one of its wholly owned subsidiaries has received approval from the US Food and Drug Administration (FDA) for a new label for Odomzo (sonidegib), an oral hedgehog inhibitor indicated for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy

  6. Natera Selected For Circulating Tumor DNA Study In Bladder Cancer
    9/20/2017

    Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Denmark's Aarhus University to leverage the company's Signatera™(RUO) personalized liquid biopsy technology to evaluate circulating tumor DNA (ctDNA) as a useful biomarker in the diagnosis and treatment of bladder cancer

  7. Spectrum Chemical Mfg. Corp. Announces U.S. Distribution Agreement With Cole-Parmer
    9/20/2017

    Spectrum Chemical Mfg. Corporation, a leading global manufacturer and distributor of fine chemicals, laboratory equipment and supplies, announced recently a new U.S. distribution agreement with Cole-Parmer

  8. Porvair Showcase Microplate Products For Drug Discovery
    9/20/2017

    Porvair Sciences offers a range of application optimised microplates and high-performance microplate equipment designed to enable drug discovery scientists to optimise sample preparation and improve productivity

  9. IDbyDNA And ARUP Laboratories Introduce Explify Respiratory: Breakthrough Technology To Diagnose Pneumonia Caused By Previously Undetected Pathogens
    9/19/2017

    ARUP Laboratories and IDbyDNA, Inc., a data analytics-driven metagenomics company, announce the launch of Explify Respiratory, a novel next-generation sequencing (NGS) test for respiratory infections

  10. Pacific Dental Services (PDS®) Supported Offices To Offer ORALDNA® Testing To Improve Oral And Systemic Health
    9/19/2017

    Over 594 PDS®-supported dental offices now have a powerful new tool to help with gum disease. A simple saline-rinse test from OralDNA® Labs measures disease-causing bacteria and helps personalize treatment